Skip to main content

Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed / Refractory B-cell Non-Hodgkin's Lymphoma

Trial Status: Active

This Phase 1b / 2 trial will evaluate Hu5F9-G4 (magrolimab) in combination with rituximab and magrolimab or in combination with R-GemOx. Magrolimab is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the cancer cells. Rituximab is a monoclonal antibody drug that is used for treatment of non-Hodgkin's lymphoma and other types of cancer. Gemcitabine and Oxaliplatin are chemotherapy commonly used with rituximab in treating NHL. The major aims of the trial are: (Phase 1b) to investigate the safety and tolerability of sequential dose cohorts and to determine a recommended Phase 2 dose for Hu5F9-G4 in combination with rituximab, and (Phase 2) to evaluate the efficacy of Hu5F9-G4 in combination with rituximab in patients with indolent lymphoma or diffuse large B-cell lymphoma as measured by the overall response rate.

Inclusion Criteria

  • Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard approved therapies
  • DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL) expressing CD 20, relapsed or refractory to at least 2 prior lines treatment containing anti-CD20 therapy
  • Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or refractory to standard approved therapies
  • DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment
  • Adequate performance status and hematological, liver and kidney functions
  • Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy

Exclusion Criteria

  • Active brain metastases
  • Prior allogeneic hematopoietic cell transplantation
  • Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents
  • Second malignancy within the last 3 years
  • Known active or chronic hepatitis B or C infection or HIV
  • Pregnancy or active breastfeeding
  • Prior CAR-T therapy


University of Alabama at Birmingham Cancer Center
Status: ACTIVE


City of Hope Comprehensive Cancer Center
Status: ACTIVE
Contact: Leslie L. Popplewell
Phone: 800-826-4673
Palo Alto
Stanford Cancer Institute Palo Alto
Status: ACTIVE


University of Chicago Comprehensive Cancer Center
Status: ACTIVE


National Institutes of Health Clinical Center
Status: ACTIVE
Contact: Mark Jason Roschewski
Phone: 240-760-6183


Beth Israel Deaconess Medical Center
Status: ACTIVE
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE


Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE


University of Minnesota / Masonic Cancer Center
Status: ACTIVE


Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE


Oklahoma City
University of Oklahoma Health Sciences Center
Status: ACTIVE


University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE


M D Anderson Cancer Center
Status: ACTIVE

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Forty Seven, Inc.

  • Primary ID 5F9003
  • Secondary IDs NCI-2017-00032
  • ID NCT02953509